BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 25522901)

  • 1. Detectability of hepatocellular carcinoma on gadoxetic acid-enhanced MRI at 3 T in patients with severe liver dysfunction: clinical impact of dual-source parallel radiofrequency excitation.
    Nishie A; Kakihara D; Asayama Y; Ushijima Y; Takayama Y; Fujita N; Shimamoto D; Shirabe K; Hida T; Honda H
    Clin Radiol; 2015 Mar; 70(3):254-61. PubMed ID: 25522901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in recipients of living-related-liver-transplantation: comparison with dynamic multidetector row computed tomography and angiography-assisted computed tomography.
    Kakihara D; Nishie A; Harada N; Shirabe K; Tajima T; Asayama Y; Ishigami K; Nakayama T; Takayama Y; Okamoto D; Fujita N; Kishimoto J; Honda H
    J Magn Reson Imaging; 2014 Nov; 40(5):1112-20. PubMed ID: 24259437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.
    Kim SH; Kim SH; Lee J; Kim MJ; Jeon YH; Park Y; Choi D; Lee WJ; Lim HK
    AJR Am J Roentgenol; 2009 Jun; 192(6):1675-81. PubMed ID: 19457834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma.
    Ooka Y; Kanai F; Okabe S; Ueda T; Shimofusa R; Ogasawara S; Chiba T; Sato Y; Yoshikawa M; Yokosuka O
    Magn Reson Imaging; 2013 Jun; 31(5):748-54. PubMed ID: 23218794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.
    Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW
    Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial?
    Kim YK; Kim CS; Han YM; Lee YH
    Clin Radiol; 2011 Jun; 66(6):489-96. PubMed ID: 21367403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of small hepatocellular carcinoma using gadoxetic acid-enhanced MRI: Is the addition of diffusion-weighted MRI at 3.0T beneficial?
    Zhao XT; Li WX; Chai WM; Chen KM
    J Dig Dis; 2014 Mar; 15(3):137-45. PubMed ID: 24354621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT.
    Baek CK; Choi JY; Kim KA; Park MS; Lim JS; Chung YE; Kim MJ; Kim KW
    Clin Radiol; 2012 Feb; 67(2):148-56. PubMed ID: 21920517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT.
    Park VY; Choi JY; Chung YE; Kim H; Park MS; Lim JS; Kim KW; Kim MJ
    Liver Int; 2014 Nov; 34(10):1593-602. PubMed ID: 24673802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging.
    Haradome H; Grazioli L; Tinti R; Morone M; Motosugi U; Sano K; Ichikawa T; Kwee TC; Colagrande S
    J Magn Reson Imaging; 2011 Jul; 34(1):69-78. PubMed ID: 21598343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas.
    Yoon JH; Lee EJ; Cha SS; Han SS; Choi SJ; Juhn JR; Kim MH; Lee YJ; Park SJ
    J Vasc Interv Radiol; 2010 Mar; 21(3):348-56. PubMed ID: 20116285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography.
    Kim YK; Kim CS; Han YM; Kwak HS; Jin GY; Hwang SB; Chung GH; Lee SY; Yu HC
    J Comput Assist Tomogr; 2009; 33(6):844-50. PubMed ID: 19940648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: initial experience.
    Lee JY; Kim SH; Jeon YH; Lee J; Kim MJ; Choi D; Lee WJ
    J Comput Assist Tomogr; 2010 Jan; 34(1):127-34. PubMed ID: 20118735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
    Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
    J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study.
    Tsurusaki M; Sofue K; Isoda H; Okada M; Kitajima K; Murakami T
    J Gastroenterol; 2016 Jan; 51(1):71-9. PubMed ID: 26130441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.